15 companies had initial public offerings and raised $6.4 billion this week, making it the most active week in the IPO market since 2007. Including deals that priced yesterday and began trading today, July saw 34 IPOs, a post-tech bubble record....read more
Last night 12 IPOs were expected to price, but only 8 did. Two deals were postponed: extended release biotech Mapi-Pharma (MAPI) and cardiovascular diagnostic firm Lantheus (LNTH). Two deals were delayed a day: osteoporosis patch biotech Zosano...read more
Bio Blast Pharma, a biotech developing treatments for rare and ultra-rare genetic diseases, raised $35 million by offering 3.2 million shares at $11, the low end of the range of $11 to $13. Bio Blast Pharma plans to list on the NASDAQ under the symbol ORPN....read more
As the IPO market prepares for the busiest week of the year, we see a broad spectrum of IPOs, including LBOs, high-growth plays, energy spinoffs and financial firms, all of which could be outnumbered by a wave of biotechs. IPO performance has stabilized after it...read more
US IPO Pricing Recap: 15 IPOs in the most active week since 2007; 66% ended at or below IPO price
15 companies had initial public offerings and raised $6.4 billion this week, making it the most active week in the IPO market since 2007. Including deals that priced yesterday and began trading today, July saw 34 IPOs, a post-tech bubble record....read more
IPO market brought down by biotech wreck and market sell off
Last night 12 IPOs were expected to price, but only 8 did. Two deals were postponed: extended release biotech Mapi-Pharma (MAPI) and cardiovascular diagnostic firm Lantheus (LNTH). Two deals were delayed a day: osteoporosis patch biotech Zosano...read more
Bio Blast Pharma prices IPO at $11, the low end of the range
Bio Blast Pharma, a biotech developing treatments for rare and ultra-rare genetic diseases, raised $35 million by offering 3.2 million shares at $11, the low end of the range of $11 to $13. Bio Blast Pharma plans to list on the NASDAQ under the symbol ORPN....read more
22 US IPOs planned for the week of Jul 28
As the IPO market prepares for the busiest week of the year, we see a broad spectrum of IPOs, including LBOs, high-growth plays, energy spinoffs and financial firms, all of which could be outnumbered by a wave of biotechs. IPO performance has stabilized after it...read more